{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:16:31Z","timestamp":1784945791836,"version":"3.55.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> The purpose of this study is to identify and characterize ocular adverse events (AEs) that are significantly associated with anti-VEGF drugs for treatment of neovascular age-related macular degeneration and compare the differences between each drug, and provide clinical reference.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Ocular AEs submitted to the US Food and Drug Administration were analyzed to map the safety profile of anti-VEGF drugs. The Pharmacovigilance tools used for the quantitative detection of signals were reporting odds ratio and bayesian confidence propagation neural network.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 10,608,503 AE reports were retrieved from FAERS, with 20,836 for ranibizumab, 19,107 for aflibercept, and 2,442 for brolucizumab between the reporting period of Q1, 2004 and Q3, 2021. We found and analyzed the different AEs with the strongest signal in each drug\u2014ranibizumab-macular ischaemia (ROR = 205.27, IC-2SD = 3.70), retinal pigment epithelial tear (ROR = 836.54, IC-2SD = 7.19); aflibercept-intraocular pressure increased (ROR = 31.09, IC-2SD = 4.61), endophthalmitis (ROR = 178.27, IC-2SD = 6.70); brolucizumab-retinal vasculitis (ROR = 2930.41, IC-2SD = 7.47) and\/or retinal artery occlusion (ROR = 391.11, IC-2SD = 6.10), dry eye (ROR = 12.48, IC-2SD = 2.88).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The presence of AEs should bring clinical attention. The use of anti-VEGF drugs should be based on the patient\u2019s underlying or present medical condition to reduce any adverse event associated with the treatment.<\/jats:p>","DOI":"10.3389\/fphar.2022.1017889","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T06:58:45Z","timestamp":1668754725000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":42,"title":["Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)"],"prefix":"10.3389","volume":"13","author":[{"given":"Pan","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linli","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangchuan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liya","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.neuron.2012.06.018","article-title":"Mechanisms of age-related macular degeneration","volume":"75","author":"Ambati","year":"2012","journal-title":"Neuron"},{"key":"B2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40942-021-00307-7","article-title":"Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: A narrative review","volume":"7","author":"Anderson","year":"2021","journal-title":"Int. J. Retina Vitr."},{"key":"B3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40942-021-00325-5","article-title":"Pipeline therapies for neovascular age related macular degeneration","volume":"7","author":"Arepalli","year":"2021","journal-title":"Int. J. Retina Vitr."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD","volume":"98","author":"Avery","year":"2014","journal-title":"Br. J. Ophthalmol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4265\/bio.17.93","article-title":"In vitro assessment of the cytotoxicity of six topical antibiotics to four cultured ocular surface cell lines","volume":"17","author":"Ayaki","year":"2012","journal-title":"Biocontrol Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s00228-014-1755-1","article-title":"Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: The analysis of the WHO database of adverse drug reactions","volume":"70","author":"Biagi","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/bs.pbr.2015.04.007","article-title":"Emerging risk factors for glaucoma onset and progression","volume":"221","author":"Blumberg","year":"2015","journal-title":"Prog. Brain Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-Year results of the ANCHOR study","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3109\/09273941003721926","article-title":"Dry eye disease as an inflammatory disorder","volume":"18","author":"Calonge","year":"2010","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B11","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1016\/j.ophtha.2016.04.056","article-title":"Anti-vascular endothelial growth factor Agents in the treatment of retinal disease: From Bench to Bedside","volume":"123","author":"Campochiaro","year":"2016","journal-title":"Ophthalmology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.ajo.2015.07.023","article-title":"Retinal pigment epithelial tear after intravitreal ranibizumab treatment for retinal Angiomatous Proliferation","volume":"160","author":"Cho","year":"2015","journal-title":"Am. J. Ophthalmol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1161\/CIRCRESAHA.108.181115","article-title":"Vascular endothelial growth factor-A Specifies formation of native collaterals and Regulates collateral growth in ischemia","volume":"103","author":"Clayton","year":"2008","journal-title":"Circ. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1001\/archopht.122.4.477","article-title":"Causes and prevalence of visual impairment among adults in the United States","volume":"122","author":"Congdon","year":"2004","journal-title":"Arch. Ophthalmol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1016\/j.ophtha.2011.05.026","article-title":"Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration","volume":"118","author":"Cunningham","year":"2011","journal-title":"Ophthalmology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"key":"B18","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1080\/14712598.2021.1915278","article-title":"Brolucizumab: A novel anti-VEGF humanized single-chain antibody fragment for treating w-AMD","volume":"21","author":"Ferro Desideri","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3928\/23258160-20140306-08","article-title":"Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents","volume":"45","author":"Fileta","year":"2014","journal-title":"Ophthalmic Surg. Lasers Imaging Retina"},{"key":"B20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1590\/s0004-27492012000200016","article-title":"Experimental models of autoimmune inflammatory ocular diseases","volume":"75","author":"Gasparin","year":"2012","journal-title":"Arq. Bras. Oftalmol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.ophtha.2012.12.009","article-title":"Streptococcus endophthalmitis outbreak after intravitreal injection of bevacizumab: One-year outcomes and investigative results","volume":"120","author":"Goldberg","year":"2013","journal-title":"Ophthalmology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000486145","article-title":"2018 Update on intravitreal injections: Euretina expert Consensus Recommendations","volume":"239","author":"Grzybowski","year":"2018","journal-title":"Ophthalmologica."},{"key":"B23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3109\/08820538.2014.959616","article-title":"Complications of subspecialty ophthalmic care: Endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor medications","volume":"29","author":"Haddock","year":"2014","journal-title":"Semin. Ophthalmol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"100680","DOI":"10.1016\/j.ajoc.2020.100680","article-title":"Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration","volume":"18","author":"Haug","year":"2020","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1001\/archopht.124.11.1532","article-title":"Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: Year 1 results of the FOCUS study","volume":"124","author":"Heier","year":"2006","journal-title":"Arch. Ophthalmol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","article-title":"Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: A Randomized Controlled study","volume":"123","author":"Holz","year":"2016","journal-title":"Ophthalmology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4803","DOI":"10.1038\/s41598-020-61571-5","article-title":"Safety profile of Epidermal growth factor receptor Tyrosine Kinase Inhibitors: A disproportionality analysis of FDA adverse event reporting system","volume":"1","author":"Huang","year":"2020","journal-title":"Sci. Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2353\/ajpath.2007.061237","article-title":"Vascular endothelial growth factor-A is a Survival factor for retinal Neurons and a critical neuroprotectant during the Adaptive response to ischemic Injury","volume":"171","author":"Kazuaki Nishijima","year":"2007","journal-title":"Am. J. Pathol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1755-3768.2009.01656.x","article-title":"Does lens status affect the course of early intraocular pressure and anterior chamber changes after intravitreal injection?","volume":"89","author":"Kerimoglu","year":"2015","journal-title":"Acta Ophthalmol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/j.1755-3768.2009.01547.x","article-title":"Retinal pigment epithelium tears after intravitreal injection of ranibizumab for predominantly classic neovascular membranes secondary to age-related macular degeneration","volume":"88","author":"Konstantinidis","year":"2010","journal-title":"Acta Ophthalmol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1038\/eye.2012.199","article-title":"Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: Incidence, features, risk factors, and outcomes","volume":"26","author":"Lyall","year":"2012","journal-title":"Eye"},{"key":"B33","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1097\/IAE.0b013e31820a67e4","article-title":"Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: Causative organisms and possible prevention strategies","volume":"31","author":"Mccannel","year":"2011","journal-title":"Retina"},{"key":"B34","doi-asserted-by":"publisher","first-page":"100862","DOI":"10.1016\/j.preteyeres.2020.100862","article-title":"Critical analysis of techniques and materials used in devices, syringes, and needles used for intravitreal injections","volume":"80","author":"Melo","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3928\/23258160-20190503-05","article-title":"Inflammatory reaction after aflibercept intravitreal injections associated with Silicone Oil Droplets Released from syringes: A case-control study","volume":"50","author":"Melo","year":"2019","journal-title":"Ophthalmic Surg. Lasers Imaging Retina"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1177\/1120672120977354","article-title":"Vision-related quality of life in patients with a history of congenital glaucoma","volume":"31","author":"Miraftabi","year":"2020","journal-title":"Eur. J. Ophthalmol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1167\/iovs.13-11821","article-title":"Fc\u03b3 receptor upregulation is associated with Immune complex inflammation in the Mouse retina and early age-related macular degeneration","volume":"55","author":"Murinello","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjo.2005.081224","article-title":"The number of people with glaucoma worldwide in 2010 and 2020","volume":"90","author":"Quigley","year":"2006","journal-title":"Br. J. Ophthalmol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/j.ophtha.2008.05.007","article-title":"Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration","volume":"115","author":"Sanjeewa","year":"2008","journal-title":"Ophthalmology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.21037\/atm.2020.02.06","article-title":"Postoperative endophthalmitis and toxic anterior segment syndrome Prophylaxis: 2020 Update","volume":"8","author":"Sengillo","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"B41","first-page":"129","article-title":"Signal detection for Cyclophosphamide: Canadian spontaneous adverse event reports (CSAER)","volume":"7","author":"Sharwan","year":"2015","journal-title":"Pain Physician"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1007\/s00417-015-2977-3","article-title":"Pigment epithelial tears after ranibizumab injection in polypoidal choroidal vasculopathy and typical age-related macular degeneration","volume":"253","author":"Shin","year":"2015","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/IAE.0b013e318195cad5","article-title":"Retinal pigment epithelial tears in ranibizumab-treated eyes","volume":"29","author":"Smith","year":"2009","journal-title":"Retina"},{"key":"B44","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3109\/09286586.2015.1090004","article-title":"Severe ocular inflammation following ranibizumab or aflibercept injections for age-related macular degeneration: A retrospective claims database analysis","volume":"23","author":"Souied","year":"2016","journal-title":"Ophthalmic Epidemiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.ajo.2008.10.005","article-title":"Enhanced Depth Imaging Optical Coherence Tomography of retinal pigment epithelial detachment in age-related macular degeneration","volume":"147","author":"Spaide","year":"2009","journal-title":"Am. J. Ophthalmol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1097\/IAE.0b013e318271f265","article-title":"Current knowledge and trends in age-related macular degeneration: today's and future treatments","volume":"33","author":"Velez-Montoya","year":"2013","journal-title":"Retina"},{"key":"B47","doi-asserted-by":"publisher","first-page":"468","DOI":"10.4103\/ijo.IJO_782_17","article-title":"Transient reversal of macular ischemia with intravitreal steroid implant injection in a case of radiation maculopathy","volume":"66","author":"Verma","year":"2018","journal-title":"Indian J. Ophthalmol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3109\/02713683.2010.484557","article-title":"Performance of tear osmolarity compared to previous diagnostic tests for dry eye diseases","volume":"35","author":"Versura","year":"2010","journal-title":"Curr. Eye Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.2147\/CIA.S143508","article-title":"Recent developments in age-related macular degeneration: A review","volume":"12","author":"Waseem","year":"2017","journal-title":"Clin. Interv. Aging"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.2147\/OPTH.S232548","article-title":"Incidence of glaucoma or ocular hypertension after repeated anti-vascular endothelial growth factor injections for macular degeneration","volume":"13","author":"Wingard","year":"2019","journal-title":"Clin. Ophthalmol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet. Glob. Health"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1017889\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T06:58:48Z","timestamp":1668754728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1017889\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":51,"alternative-id":["10.3389\/fphar.2022.1017889"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1017889","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,18]]},"article-number":"1017889"}}